Anavex Life Sciences Corp. (AVXL)

Market Cap	447.63M
Revenue (ttm)	n/a
Net Income (ttm)	-46.38M
Shares Out	89.35M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,734,007
Open	4.87
Previous Close	4.85
Day's Range	4.73 - 5.19
52-Week Range	2.86 - 13.99
Beta	1.17
Analysts	Strong Buy
Price Target	22.00 (+339.12%)
Earnings Date	Feb 11, 2026

About AVXL

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: AVXL
• Website: https://www.anavex.com

Analyst Summary

According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 339.12% from the latest price.

Price Target

$22.0

(339.12% upside)

Analyst Consensus: Strong Buy